INTRINSIC LIFESCIENCES, LLC
Medtech · Private
Point-of-care lateral flow assay device to quantify urinary hepcidin for non-invasive iron deficiency diagnosis in children
- Grants
- $6.2M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 15
- 6 granted · 9 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Serum Hepcidin Immunoassay: Laboratory to Marketplace | $1,391,549 | |
| Federal grant | Department of Health and Human Services · Phase II · Serum Hepcidin Immunoassay: Laboratory to Marketplace | $1,368,932 | |
| Federal grant | Department of Health and Human Services · Phase II · supplemental funding for Phase 2B NIDDK grant | $181,804 | |
| Federal grant | Department of Health and Human Services · Phase II · Monoclonal Sandwich ELISA for Serum Erythroferrone for Clinical Assessment of Ineffective Erythropoiesis | $810,487 | |
| Federal grant | Department of Health and Human Services · Phase II · Monoclonal Sandwich ELISA for Serum Erythroferrone for Clinical Assessment of Ineffective Erythropoiesis | $676,117 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Point-of-Care Device for Urinary Hepcidin to Detect Iron Deficiency in Children and Adolescents | $960,522 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Point-of-Care Device for Urinary Hepcidin to Detect Iron Deficiency in Children and Adolescents | $788,664 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1180 | IMMUNO TECHNOLOGIES INC | — | — |
| 1181 | PERFUSIO CORP. | — | $11M |
| 1182 | INIA BIOSCIENCES, INC. | — | $200K |
| 1183 | INTRINSIC LIFESCIENCES, LLC | — | — |
| 1184 | CubeWorks, Inc. | — | $18M |
| 1185 | NOVOTHELIUM, LLC | — | — |
| 1186 | Jana Care, Inc. | — | $33M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Antibodies To Human Erythroferrone And Uses Thereofgranted
- Kits For Detection Of Hepcidinapplication
- Antibodies To Human Erythroferrone And Uses Thereofgranted
- Humanized Anti-hepcidin Antibodies And Uses Thereofgranted
- Anti-hepcidin Antibodies And Uses Thereofgranted
- Anti-hepcidin Antibodies And Uses Thereofgranted
- Anti-hepcidin Antibodies And Uses Thereofgranted
- Method Of Treating Iron Deficiency Anemiaapplication
- Anti-hepcidin Antibodies And Uses Thereofapplication
- Antibodies To Human Erythroferrone And Uses Thereofapplication
- Kits For Detection Of Hepcidinapplication
- Kits for Detection of Hepcidinapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.